The Medical Advisor

Low-dose naltrexone (LDN) is generating buzz as a potential treatment for a range of conditions, from chronic pain to autoimmune disorders, offering new hope for patients with difficult-to-manage symptoms. While hailed for its symptom relief, some health experts warn that LDN may not tackle the underlying causes of disease. The question remains: Is this affordable, underutilized drug a breakthrough or merely a temporary fix? A Lifeline Linda Elsgood felt unstoppable. A mother of two and full-time bank manager, she balanced work and family with ease. “I was Wonder Woman. I could do anything,” she told The Epoch Times. But when both her parents fell ill, the stress of caregiving began to take its toll. Soon after, Elsgood began experiencing troubling symptoms: numbness in her leg and face, extreme fatigue, and vision issues. In 2000, she was diagnosed with relapsing-remitting multiple sclerosis (MS). By 2003, the disease had progressed to secondary progressive MS, and her doctors informe...

Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...

Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (77 cases) Brain Cancer (including Glioblastoma) (119 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (29 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (51 cases) Esophageal and Stomach cancer (21 cases) Endometrial Cancer (9 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (21 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (27 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (40 cases) Leukemia (9 cases) Lymphoma (23 cases) Melanoma (refer to Skin Cancer ) ...